

## Special Issue

# How COVID-19 Affects Cancer Patients

### Message from the Guest Editor

The effects of COVID-19 vary according to the patients' characteristics and tumor type. Older patients and those with hematological diseases are most at risk. In patients with blood cancers, COVID-19 has a greater impact and degree of lethality. Furthermore, patients with lung and prostate cancer appear to be at a reduced risk of suffering from COVID-19 infection and dying from it, while women with breast and gynecological cancers are those with the most minor risk of infection. Novel research in this area of interest will be able to explain the variation in the risks associated with COVID-19 based on the characteristics and tumor type of cancer patients.

---

### Guest Editor

Dr. Maria Fiore

Department of Medical and Surgical Science and Advanced Technologies "G.F. Ingrassia", University of Catania, 95123 Catania, Italy

---

### Deadline for manuscript submissions

31 January 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/170636](https://mdpi.com/si/170636)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)